eligibility_summary
Adults ≥18 with metastatic/unresectable epithelial tumors (non-ovarian) after ≥1 prior therapy. Expansion: mPDAC, mCRC, PD-(L)1–exposed solids, mCRPC. Measurable disease (except prostate per PCWG3). ECOG 0–1, adequate organs, CrCl ≥50, contraception, washouts. Exclude: unresolved ≥G1 tox, recent trials/surgery/live vax, uncontrolled illness/CNS disease, uncontrolled HIV/HBV/HCV, pembro: immunosuppression/autoimmune/pneumonitis, mAb allergy (bev/pembro), oxaliplatin neuropathy ≥G3.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06576037 (Phase Ib) tests CBP-1019 combinations in metastatic TRPV6-overexpressing epithelial tumors. Interventions and mechanisms: • CBP-1019: investigational IV targeted agent designed to inhibit the TRPV6 calcium channel, aiming to reduce Ca2+-driven tumor growth/survival signaling. • FOLFOX: 5‑fluorouracil (antimetabolite, thymidylate synthase inhibitor) + leucovorin (folinic acid, enhances 5‑FU TS binding) + oxaliplatin (platinum cytotoxic, DNA crosslinker). • Bevacizumab: monoclonal antibody anti‑VEGF‑A, anti‑angiogenic. • Pembrolizumab: monoclonal antibody anti‑PD‑1, restores T‑cell antitumor activity. • Enzalutamide: small‑molecule androgen receptor antagonist, blocks AR signaling. Targets/pathways: TRPV6-high tumor cells (Ca2+ influx), DNA synthesis/repair in proliferating tumor cells, VEGF‑driven tumor angiogenesis (endothelial cells), PD‑1/PD‑L1 immune checkpoint (T cells), and AR pathway in CRPC cells.